Phase IV EORTC Quality of Life Module for Patients With Chronic Myeloid Leukemia
NCT ID: NCT03075969
Last Updated: 2019-03-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
337 participants
OBSERVATIONAL
2017-08-03
2019-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
An Observational Study on The Health Related Quality of Life in Patients With Chronic Lymphocytic Leukaemia
NCT01395615
A Study for PRO of CML in Real Word
NCT05092048
Mid-to Long-Term Outcomes in Chronic Myeloid Leukemia (CML) Patients With Complete Cytogenetic Response After Imatinib as First Line Therapy
NCT00896129
Real-World Disease Management and Outcomes in Chronic Myeloid Leukaemia
NCT05893836
Treatment of Acute Myeloblastic Leukemia in Younger Patients
NCT00390715
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient with confirmed diagnosis of Philadelphia chromosome positive and/or BCR-ABL positive chronic myeloid leukemia (CML).
* Written informed consent.
* Patients enrolled in investigational drug-trials or other type of clinical trials are also eligible.
Exclusion Criteria
* Patients who are unable to speak and read the language of the questionnaire.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Gruppo Italiano Malattie EMatologiche dell'Adulto
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Fabio Efficace, PhD
Role: STUDY_CHAIR
GIMEMA Foundation
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Winship Cancer Institute of Emory University
Emory, Georgia, United States
Innsbruck Medical University
Innsbruck, , Austria
Complexo Hospital de Clinicas da Universidade Federal do Parana
Paranã, , Brazil
Guangdong Medical University
Guangdong, , China
Universität Heidelberg
Heidelberg, , Germany
Baghdad Teaching Hospital
Baghdad, , Iraq
Azienda Ospedaliero - Universitaria Ospedali Riuniti Umberto I - G.M. Lancisi - G. Salesi
Ancona, , Italy
Azienda Ospedaliero-Universitaria Policlinico Consorziale
Bari, , Italy
Department of Oncology and Hematology, O.U. of Hematology, S. Orsola-Malpighi University Hospital, Bologna
Bologna, , Italy
Sezione di Ematologia e Trapianti Spedali Civili
Brescia, , Italy
CTMO - Ematologia - Ospedale Binaghi
Cagliari, , Italy
Divisione clinicizzata di Ematologia - Dipartimento di Scienze Mediche - Osp. Ferrarotto
Catania, , Italy
Clinica Ematologica - Dipartimento di Medicina Interna - IRCCS San Martino - IST
Genova, , Italy
Lecce ASL Le/1 P.O. Vito Fazzi - U.O. di Ematologia ed UTIE
Lecce, , Italy
U.O. Ematologia 1 - Centro Trapianti di Midollo - Ospedale Maggiore Milano
Milan, , Italy
Divisione di Ematologia - Dip. Di Medicina Clinica e Sperimentale & BRMA - Università Piemonte Orientale "Amedeo Avogato"
Novara, , Italy
Azienda Ospedaliera Universitaria - Policlinico Paolo Giaccone
Palermo, , Italy
U.O.C. di Ematologia e CTMO Az. Ospedaliero Universitaria Parma
Parma, , Italy
Div. di Ematologia IRCCS Policlinico S. Matteo
Pavia, , Italy
Dipartimento di Oncologia ed Ematologia - AUSL Ospedale G. da Saliceto
Piacenza, , Italy
Dipartimento Oncologico - Ospedale S.Maria delle Croci
Ravenna, , Italy
Unità Operativa Complessa di Ematologia - Arcispedale S. Maria Nuova
Reggio Emilia, , Italy
Clinica di Ematologia - Policlinico Umberto I- Università degli Studi "Sapienza"
Roma, , Italy
Divisione di Ematologia - Ospedale S.Eugenio
Roma, , Italy
Divisione Ematologia - Università Campus Bio-Medico
Roma, , Italy
Università Cattolica del Sacro Cuore - Policlinico A. Gemelli
Roma, , Italy
U.O. di Ematologia - Casa Sollievo della Sofferenza
San Giovanni Rotondo, , Italy
Ematologia - AOU Sassari
Sassari, , Italy
U.O di Ematologia d. U. - Azienda Ospedaliera Universitaria Integrata Verona
Verona, , Italy
Ospedale San Bortolo
Vicenza, , Italy
UCSI University, Faculty of Pharmaceutical Sciences
Kuala Lumpur, , Malaysia
Eindhoven and Tilburg University
Eindhoven, , Netherlands
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
QoL-CML 0916
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.